Dendreon Pharmaceuticals has signed a 10-year lease agreement to maintain its 155,000-square-foot immunotherapy manufacturing facility in Union City, Ga.
Dendreon is the maker of Provenge, an immunotherapy treatment for prostate cancer.
“Dendreon has been a proud member of the greater Atlanta community since 2009, and we are thrilled to extend our presence here,” said Christina Yi, chief operations officer at Dendreon. “Over the past 10 years, we have grown locally, building key relationships that allow us to sustain our unique business. We look forward to continuing to attract diverse local talent who will help us bring Provenge to more men with advanced prostate cancer.”
Once a public company based in Seattle, Dendreon is now a private company based in Seal Beach, Calif.